Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 3 Date: 19 Jan 2024
Reviewer:  Chun-Ming Hong
Reviewer's report:
This study provides real-world comparisons between a new drug and an established DAA.
However, the questions that I raised (the percentages of HBV and HIV co-infection) were not
elucidated.
Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 3 Date: 19 Jan 2024
Reviewer:  Chun-Ming Hong
Reviewer's report:
This study provides real-world comparisons between a new drug and an established DAA.
However, the questions that I raised (the percentages of HBV and HIV co-infection) were not
elucidated.
Please review this paper.
user
Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 3 Date: 19 Jan 2024
Reviewer:  Chun-Ming Hong
Reviewer's report:
This study provides real-world comparisons between a new drug and an established DAA.
However, the questions that I raised (the percentages of HBV and HIV co-infection) were not
elucidated.
assistant